ICER Issues Cost-Benefit Analysis on Three Sickle Cell Disease Treatments

The Institute for Clinical and Economic Review (ICER) released a draft cost-benefit analysis comparing three sickle cell disease treatments — Novartis’ Adakveo, Global Blood Therapeutics’ Oxbryta and Emmaus Life Sciences’ Endari — predicting that the expected cost would exceed the benefit for all three products.
Source: Drug Industry Daily